Ken Walz has worked for more than 25 years in the biotech, diagnostics, and medical device industries in business development and finance roles and is particularly interested in the application of disruptive technologies to address inefficiencies in the healthcare system. He brings broad experience in commercial operations and strategy development and has extensive experience leading transaction processes. At Popper and Company, he assists clients in all aspects of strategy and corporate development including strategic partnership development, transaction process management, and health economic modeling.
Prior to Popper and Company, Ken held senior positions at MDS Proteomics and Becton Dickinson. Ken holds a BA in Economics from the University of Maryland Baltimore County and an MS in Finance from Loyola College of Maryland.